Pharma/Biotech - Page 1 | TalkMarkets
All Posts > Content under Pharma/Biotech
1 to 16 of 1973 Posts
1 2 3 ... 124
5 Top-Rated Biotech Stocks With Big Upside Potential
Article By: TipRanks
Wednesday, June 28, 2017 6:58 AM EDT
Given the risk inherent in this sector it is important to pick stocks wisely- and choosing stocks recommended by top analysts is one way of pinpointing top biotech stocks.
In this article: MDWD, BDSI, PTLA, ALXN, CUTR
Read
Will SMH’s Sickness Sink The Market?
Article By: Geoff Bysshe
Tuesday, June 27, 2017 10:08 PM EDT
We may be about to find out just how sick this market is. When a member of a family catches a nasty cold it’s never fun. If the family is healthy then the cold stays contained, but we all know what happens when the cold is able to spread.
In this article: IBB, SMH Also: QQQ, DIA, GDX, GLD, IWM, IYR, IYT, KRE, SPY, TAN, TLT, USO, UUP, XLU, XME, XRT
Read
5 Biomedical Stocks That Are Expected To Surge
Article By: Zacks Investment Research
Tuesday, June 27, 2017 5:01 PM EDT
Every investor struggles with balancing risk and reward when choosing their investments. Biomedical companies are known to offer large capital gains and growth prospects, yet they do not always come to fruition.
In this article: GERN, REGN, KDMN, ENZ, AVXL Also: JNJ
Read
Mersana Therapeutics Kicks Off A Major IPO Week
Article By: Don Dion
Monday, June 26, 2017 6:49 PM EDT
We like Mersana's partnerships with major pharma firms.The pipeline overall is OK and the company notes in its SEC Filings that post-IPO its goal is to file one new IND every 12-24 months. We recommend investors consider a modest allocation to MRSN.
In this article: MRSN Also: AZN, BMY, LLY, NVS, PFE, SNY, IMGN, IMMU, SGEN, ABBV
Read
The AHCA: Will It Stall The Bull Market?
Article By: TheoTrade
Saturday, June 24, 2017 5:37 PM EDT
The market is pricing in the economy maintaining the current pace which could mean stocks will rally when something gets done and sell off if nothing gets done.
In this article: IBB, VIX
Read
Biotechnology Stocks - Repligen Major Breakout
Article By: Taki Tsaklanos
Friday, June 23, 2017 5:10 PM EDT
The biotech index is still way below its all-time highs. However, Repligen managed to climb to its highs, which suggests a sector leader.
In this article: RGEN
Read
Sector Showcase: Biotech Stocks Are The "Transformer" Michael Bay Should Be Watching
Article By: Matt Weller
Friday, June 23, 2017 2:45 PM EDT
The world's largest biotech fund, the iShares Nasdaq Biotech ETF (IBB​), has had a quiet couple of months. For the last four months, the fund has been consolidating in a tight range between about 285.00 and 303.00.
In this article: IBB Also: CELG, REGN, AMGN, BIIB, GILD
Read
NVS Scores With Positive Data, Shire ADHD Drug Gets FDA Nod
Article By: Arpita Dutt
Friday, June 23, 2017 10:00 AM EDT
This week’s highlights include positive data from Novartis while the FDA approved a couple of attention deficit hyperactive disorder (ADHD) drugs.
In this article: BMY, MRK, NVO, NVS, RHHBY, SHPG, NEOS
Read
Premarket Biotech Digest – DMPI Receives Approval, PFE Slapped From FDA
Article By: KKD Healthcare Analytics
Friday, June 23, 2017 9:31 AM EDT
DelMar Pharmaceuticals announced that it has received Institutional Review Board approval to conduct a Phase 3 clinical trial. Pfizer received a setback from the FDA. Roche announced receiving the FDA approval .
In this article: PFE, RHHBY, TROV, QGEN, DMPI, IONS, VTGN, PRTO
Read
5 Marijuana Stocks With Gross Margins Well Above Their Industry Peers
Article By: Lorimer Wilson
Friday, June 23, 2017 5:22 AM EDT
Identifying companies with high gross margins in the young marijuana industry is important because operating costs are likely to decrease as the industry matures leaving these companies with high earnings potential. Here are the top 5 such companies.
In this article: IVITF, CMMDF, OGRMF, CAMDF, APHQF
Read
Biotech Breakout: Healthcare Stocks Lead The Way
Article By: Rod Raynovich
Thursday, June 22, 2017 2:40 PM EDT
The BIO 2017 International Convention in San Diego got a big boost with investors piling into biotechnology and healthcare stocks. 2017 Biotech Run Has Been Impressive but what can we buy now?
In this article: XBI, XLV, IBB, AGIO, BLUE, BMY, CELG, CLVS, EPZM, EXEL, INCY, KITE, LOXO, MRK, NVS, PBYI, RHHBY, SGEN, TSRO
Read
Corbus Moves Lead Candidate To Phase 3 Study, Offers Good Investment Deal
Article By: KKD Healthcare Analytics
Thursday, June 22, 2017 9:33 AM EDT
Corbus has several catalysts coming up as it progresses with the testing of its lead drug candidate for different indications. Its earliest upcoming catalyst is in the fourth quarter.
In this article: CRBP
Read
Is The Market A False Hologram We’re Trained To See?
Article By: Michele Schneider
Tuesday, June 20, 2017 9:48 PM EDT
Early today, the Dow Jones made another new all-time high. Bullish, right? Technically, yes. Although the Russell 2000 provided a different experience. What are some of the different angles investors perceive?
In this article: IBB, QQQ, IWM, IYT, KRE, SMH, XRT Also: GDX, GLD, IYR, SPY, TAN, TLT, USO, UUP, XLU
Read
Biogen Ready For A Sizable Bounce
Article By: Bob Lang
Tuesday, June 20, 2017 5:45 PM EDT
The big biopharma company Biogen seems poised for an upside pop soon based on recent turnover and bullish price divergence. It has a good chance to reach the 200 ma for the first time since breaking down in late April.
In this article: BIIB
Read
Axsome Looks Good On Multiple Catalysts: Fast Track Designation Eases Liquidity Concerns
Article By: KKD Healthcare Analytics
Tuesday, June 20, 2017 11:27 AM EDT
Axsome Therapeutics Inc. (AXSM) has multiple catalysts coming up in the near future as it has two main drug candidates under Phase 3 testing for multiple conditions. The stock has shown strength as it gained over 12 percent in the past one month.
In this article: AXSM
Read
Jefferies Sees $60-$75 Per Share Buyout Range For Mallinckrodt
Article By: The Fly
Tuesday, June 20, 2017 10:44 AM EDT
Amid speculation that Mallinckrodt is seeking strategic alternatives, Jefferies analyst Anthony Petrone explored leveraged buyout scenarios in order to gauge the feasibility of a sponsor-led transaction.
In this article: MNK
Read
1 to 16 of 1973 Posts
1 2 3 ... 124